Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of OLMA is 41 and suggests 167% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell